At the trigeminal level, ADM_12 was able to reduce orofacial pain in a model of temporomandibular joint inflammation [23], and to counteract trigeminal hyperalgesia in a model of migraine pain, together with decreased Trpa1 and neuropeptide mRNA expression levels in specific areas implicated in trigeminal pain [24]. Here, TRPA1 is linked to migraine disorder.